A Phase II multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy (CRT)

IRB/UVA Tracking #
21355
Contact
Amy Smith
Contact Email
Contact Phone
1.434.243.1619
Phase
III
Primary purpose
Supportive Care
Cancer PI
Paul W Read
Status
OPEN TO ACCRUAL
Ages
Adult